

## Report on Compliance with respect to NICE Technology Appraisals Produced by Medicines Information, Pharmacy Directorate

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
443	April 2017	Obeticholic acid for treating primary biliary cholangitis	Being Processed		
442	April 2017	Ixekizumab for treating moderate to severe plaque psoriasis	Being Processed		
441	April 2017	Daclizumab for treating relapsing–remitting multiple sclerosis	TA not applicable to this organisation	TA not applicable to this organisation	25/5/17
440	April 2017	Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine	Yes	CHFT Complies with this NICE TA	25/5/17
439	March 2017	Cetuximab and panitumumab for previously untreated metastatic colorectal cancer	Yes	CHFT Complies with this NICE TA	25/5/17
438	March 2017	Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)	Yes	CHFT Complies with this NICE TA	25/5/17

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
437	March 2017	Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)	Yes	CHFT Complies with this NICE TA	25/5/17
436	March 2017	Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)	Yes	CHFT Complies with this NICE TA	25/5/17
435	March 2017	Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)	Yes	CHFT Complies with this NICE TA	25/5/17
434	March 2017	Elotuzumab for previously treated multiple myeloma (terminated appraisal)	Yes	CHFT Complies with this NICE TA	25/5/17
433	February 2017	Apremilast for treating active psoriatic arthritis	Yes	CHFT Complies with this NICE TA	30/3/17
432	February 2017	Everolimus for advanced renal cell carcinoma after previous treatment	Being Processed		
431	January 2017	Mepolizumab for treating severe refractory eosinophilic asthma	Being Processed		
430	January 2017	Sofosbuvir–velpatasvir for treating chronic hepatitis C	Yes	CHFT Complies with this NICE TA	30/3/17
429	January 2017	Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation	Being Processed		
428	January 2017	Pembrolizumab for treating PDL1-positive non-small-cell lung cancer after chemotherapy	Being Processed		
427	January 2017	Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib	Being Processed		
426	December 2016	Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia	Being Processed		
425	December 2016	Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia	Being Processed		

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
424	December 2016	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer	Being Processed		
423	December 2016	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens	Being Processed		
422	December 2016	Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	Being Processed		
421	December 2016	Everolimus with exemestane for treating advanced breast cancer after endocrine therapy	Being Processed		
420	December 2016	Ticagrelor for preventing atherothrombotic events after myocardial infarction	Being Processed		
419	November 2016	Apremilast for treating moderate to severe plaque psoriasis	Yes	CHFT Complies with this NICE TA	25/5/17
418	November 2016	Dapagliflozin in triple therapy for treating type 2 diabetes	Being Processed		
417	November 2016	Nivolumab for previously treated advanced renal cell carcinoma	TA not applicable to this organisation	TA not applicable to this organisation	26/1/17
416	October 2016	Osimertinib for treating locally advanced or metastatic EGFR T790M mutationpositive non-small-cell lung cancer	Yes	CHFT Complies with this NICE TA	26/1/17
415	October 2016	Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor	Yes	CHFT Complies with this NICE TA	26/1/17
414	October 2016	Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma	TA not applicable to this organisation	TA not applicable to this organisation	26/1/17
413	October 2016	Elbasvir-grazoprevir for treating chronic hepatitis C	Yes	CHFT Complies with this NICE TA	26/1/17
412	September 2016	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases	TA not applicable to this organisation	TA not applicable to this organisation	24/11/16
411	September 2016	Necitumumab for untreated advanced or metastatic squamous non-small-cell lung	Yes	CHFT Complies with this NICE TA	24/11/16

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		cancer			
410	September 2016	Talimogene laherparepvec for treating unresectable metastatic melanoma	TA not applicable to this organisation	TA not applicable to this organisation	24/11/16
409	September 2016	Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion	Yes	CHFT Complies with this NICE TA	26/1/17
408	September 2016	Pegaspargase for treating acute lymphoblastic leukaemia	TA not applicable to this organisation	TA not applicable to this organisation	24/11/16
407	September 2016	Secukinumab for active ankylosing spondylitis after treatment with nonsteroidal anti-inflammatory drugs or TNF-alpha inhibitors	Yes	CHFT Complies with this NICE TA	24/11/16
406	September 2016	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non small-cell lung cancer	Yes	CHFT Complies with this NICE TA	24/11/16
405	August 2016	Trifluridine–tipiracil for previously treated metastatic colorectal cancer	Yes	CHFT Complies with this NICE TA	24/11/16
404	August 2016	Degarelix for treating advanced hormone-dependent prostate cancer	Yes	CHFT Complies with this NICE TA	30/3/17
403	August 2016	Ramucirumab for previously treated locally advanced or metastatic non-smallcell lung cancer	Yes	CHFT Complies with this NICE TA	24/11/16
402	August 2016	Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin	Yes	CHFT Complies with this NICE TA	24/11/16
401	Aug 2016	Bosutinib for previously treated chronic myeloid leukaemia	Yes	CHFT Complies with this NICE TA	24/11/16
400	July 2016	Nivolumab in combination with ipilimumab for treating advanced melanoma	TA not applicable to this organisation	TA not applicable to this organisatio	29/9/16
399	July 2016	Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts	Yes	CHFT Complies with this NICE TA	24/11/16
398	July 2016	Lumacaftor–ivacaftor for treating cystic	TA not applicable to this organisation	TA not applicable to this	29/9/16

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		fibrosis homozygous for the F508del mutation		organisatio	
397	June 2016	Belimumab for treating active autoantibody-positive systemic lupus erythematosus	Yes	CHFT Complies with this NICE TA	21/7/16
396	June 2016	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma	TA not applicable to this organisation	TA not applicable to this organisatio	
395	June 2016	Ceritinib for previously treated anaplastic lymphoma kinase positive nonsmall-cell lung cancer	Yes	CHFT Complies with this NICE TA	30/3/17
394	June 2016	Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	Yes	CHFT Complies with this NICE TA	26/1/17
393	June 2016	Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia0	Yes	CHFT Complies with this NICE TA	26/1/17
392	June 2016	Adalimumab for treating moderate to severe hidradenitis suppurativa	TA not applicable to this organisation	TA not applicable to this organisation	21/7/16
391	May 2016	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel	Yes	CHFT Complies with this NICE TA	30/3/17
390	May 2016	Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes	Yes	CHFT Complies with this NICE TA	21/7/16
389	April 2016	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer	Yes	CHFT Complies with this NICE TA	30/3/17
388	April 2016	Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction	Yes	CHFT Complies with this NICE TA	21/7/16
387	April 2016	Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	Yes	CHFT Complies with this NICE TA	30/3/17
386	March 2016	Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with	Yes	CHFT Complies with this NICE TA	26/4/16

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		myelofibrosis			
385	Feb 2016	Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia	Yes	CHFT Complies with this NICE TA	26/4/16
384	Feb 2016	Nivolumab for treating advanced (unresectable or metastatic) melanoma	TA not applicable to this organisation	TA not applicable to this organisation	26/4/16
383	Feb 2016	TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis	Yes	CHFT Complies with this NICE TA	26/4/16
382		Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)	Yes	CHFT Complies with this NICE TA	26/4/16
381		Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy	Yes	CHFT Complies with this NICE TA	26/4/16
380		Panobinostat for treating multiple myeloma after at least 2 previous treatments	Yes	CHFT Complies with this NICE TA	26/4/16
379		Nintedanib for treating idiopathic pulmonary fibrosis	Yes	CHFT Complies with this NICE TA	26/4/16
378		Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy	Yes	CHFT Complies with this NICE TA	26/4/16
377		Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	Yes	CHFT Complies with this NICE TA	26/4/16
376		Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases	TA not applicable to this organisation	TA not applicable to this organisation	26/4/16
375		Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not	Yes	CHFT Complies with this NICE TA	26/4/16

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		previously treated with DMARDs or after conventional DMARDs only have failed			
374		Erlotinib and gefitinib for treating nonsmall-cell lung cancer that has progressed after prior chemotherapy	Yes	CHFT Complies with this NICE TA	26/4/16
373		Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	Yes	CHFT Complies with this NICE TA	26/4/16
372		Apremilast for treating active psoriatic arthritis	Yes	CHFT Complies with this NICE TA	26/4/16
371		Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane	Yes	CHFT Complies with this NICE TA	26/4/16
370		Bortezomib for previously untreated mantle cell lymphoma	Yes	CHFT Complies with this NICE TA	26/4/16
369		Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears	Yes	CHFT Complies with this NICE TA	21/1/2016
368		Apremilast for treating moderate to severe plaque psoriasis – not recommended	Yes	CHFT Complies with this NICE TA	21/1/2016
367		Vortioxetine for treating major depressive episodes	TA not applicable to this organisation	TA not applicable to this organisation	21/1/2016
366		Pembrolizumab for advanced melanoma not previously treated with ipilimumab	TA not applicable to this organisation	TA not applicable to this organisation	21/1/2016
365		Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C	Yes	CHFT Complies with this NICE TA	21/1/2016
364		Daclatasvir for treating chronic hepatitis C	Yes	CHFT Complies with this NICE TA	21/1/2016
363		Ledipasvir–sofosbuvir for treating chronic hepatitis C	Yes	CHFT Complies with this NICE TA	21/1/2016
362		Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell	Yes	CHFT Complies with this NICE TA	26/11/2015

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		lung cancer (terminated appraisal)			
361		Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal)	Yes	CHFT Complies with this NICE TA	26/11/2015
360		Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer	Yes	CHFT Complies with this NICE TA	26/11/2015
359		Idelalisib for treating chronic lymphocytic leukaemia	Yes	CHFT Complies with this NICE TA	21/1/2016
358		Tolvaptan for treating autosomal dominant polycystic kidney disease	Yes		
357		Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab	TA not applicable to this organisation	TA not applicable to this organisation	26/11/2015
356		Ruxolitinib for treating polycythaemia vera (terminated appraisal)	Yes	CHFT Complies with this NICE TA	26/11/2015
355		Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation	Yes	CHFT Complies with this NICE TA	26/11/2015
354		Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism	Yes	CHFT Complies with this NICE TA	26/11/2015
353		Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)	Yes	CHFT Complies with this NICE TA	26/11/2015
352		Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy	Yes	CHFT Complies with this NICE TA	26/11/2015
351		Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal)	Yes	CHFT Complies with this NICE TA	26/11/2015
350		Secukinumab for treating moderate to severe	Yes	CHFT Complies with this	26/11/2015



Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		plaque psoriasis		NICE TA	
349		Dexamethasone intravitreal implant for treating diabetic macular oedema	Yes	CHFT Complies with this NICE TA	26/11/2015
348		Everolimus for preventing organ rejection in liver transplantation	TA not applicable to this organisation	TA not applicable to this organisation	26/11/2015
347		Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer	Yes	CHFT Complies with this NICE TA	26/11/2015
346		Aflibercept for treating diabetic macular oedema	Yes	CHFT Complies with this NICE TA	26/11/2015
345		Naloxegol for treating opioid-induced constipation	Yes	CHFT Complies with this NICE TA	21/1/2016
344		<a href="#">Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia</a>	Yes	CHFT Complies with this NICE TA	26/11/2015
343		<a href="#">Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia</a>	Yes	CHFT Complies with this NICE TA	26/11/2015
342		<a href="#">Vedolizumab for treating moderately to severely active ulcerative colitis</a>	Yes	CHFT Complies with this NICE TA	26/11/2015
341		<a href="#">Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary</a>	Yes	CHFT Complies with this NICE TA	26/11/2015
340		<a href="#">Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313)</a>	Yes	CHFT Complies with this NICE TA	24/9/2015
339		<a href="#">Omalizumab for previously treated chronic spontaneous urticaria</a>	Yes	CHFT Complies with this NICE TA	26/11/2015
338		<a href="#">Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide</a>	Yes	CHFT Complies with this NICE TA	14/5/2015
337		<a href="#">Rifaximin for preventing episodes of overt hepatic encephalopathy</a>	Yes	CHFT Complies with this NICE TA	24/9/2015
336		<a href="#">Empagliflozin in combination therapy for</a>	Yes	CHFT Complies with this	14/5/2015

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		<a href="#">treating type 2 diabetes</a>		NICE TA	
335		<a href="#">Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome</a>	Yes	CHFT Complies with this NICE TA	26/11/2015
334		<a href="#">Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated)</a>	Yes	CHFT Complies with this NICE TA	26/11/2015
333		<a href="#">Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment</a>	Yes	CHFT Complies with this NICE TA	26/11/2015
332		<a href="#">Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer</a>	Yes	CHFT Complies with this NICE TA	14/5/2015
331		<a href="#">Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C</a>	Yes	CHFT Complies with this NICE TA	24/9/2015
330		<a href="#">Sofosbuvir for treating chronic hepatitis C</a>	Yes	CHFT Complies with this NICE TA	24/9/2015
329		<a href="#">Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)</a>	Yes	CHFT Complies with this NICE TA	24/9/2015
328		<a href="#">Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)</a>	Yes	CHFT Complies with this NICE TA	22/1/2015
327		<a href="#">Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism</a>	Yes	CHFT Complies with this NICE TA	14/5/2015
326		<a href="#">Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196)</a>	Yes	CHFT Complies with this NICE TA	22/1/2015
325		<a href="#">Nalmefene for reducing alcohol consumption in people with alcohol dependence</a>	Yes	CHFT Complies with this NICE TA	22/1/2015

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
324		<a href="#">Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88)</a>	Yes	CHFT Complies with this NICE TA	24/7/2015
323		<a href="#">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142)</a>	Yes	CHFT Complies with this NICE TA	22/1/2015
322		<a href="#">Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality</a>	Yes	CHFT Complies with this NICE TA	4/12/2014
321		<a href="#">Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
320		<a href="#">Dimethyl fumarate for treating relapsing-remitting multiple sclerosis</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
319		<a href="#">Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
318		<a href="#">Lubiprostone for treating chronic idiopathic constipation</a>	Yes	CHFT Complies with this NICE TA	26/7/15
317		<a href="#">Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)</a>	Yes	CHFT Complies with this NICE TA	26/1/15
316		<a href="#">Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen</a>	Yes	CHFT Complies with this NICE TA	
315		<a href="#">Canagliflozin in combination therapy for treating type 2 diabetes</a>	Yes	CHFT Complies with this NICE TA	
314		<a href="#">Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120)</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
313		<a href="#">Psoriatic arthritis (active) - ustekinumab</a>	Yes	CHFT Complies with this NICE TA	
312		<a href="#">Multiple sclerosis (relapsing-remitting) - alemtuzumab</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
311		<a href="#">Multiple myeloma - bortezomib (induction therapy)</a>	Yes	CHFT Complies with this NICE TA	
310		<a href="#">Lung cancer (non small cell, EGFR mutation positive) - afatinib</a>	Yes	CHFT Complies with this NICE TA	
309		<a href="#">Lung cancer (non small cell, non squamous) - pemetrexed</a>	Yes	CHFT Complies with this NICE TA	
308		<a href="#">Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids)</a>	Yes	CHFT Complies with this NICE TA	
307		<a href="#">Colorectal cancer (metastatic) - aflibercept</a>	Yes	CHFT Complies with this NICE TA	
306		<a href="#">Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy</a>	Yes	CHFT Complies with this NICE TA	
305		<a href="#">Macular oedema (central retinal vein occlusion) - aflibercept solution for injection</a>	Yes	CHFT Complies with this NICE TA	
304		<a href="#">Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44)</a>	Yes	CHFT Complies with this NICE TA	
303		<a href="#">Teriflunomide for treating relapsing-remitting multiple sclerosis</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
302		<a href="#">Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal)</a>	Yes	CHFT Complies with this NICE TA	
301		<a href="#">Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271)</a>	Yes	CHFT Complies with this NICE TA	
300		<a href="#">Hepatitis C (children and young people) - peginterferon alfa and ribavirin</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
299		<a href="#">Leukaemia (chronic myeloid) - bosutinib</a>	Yes	CHFT Complies with this NICE TA	
298		<a href="#">Choroidal neovascularisation (pathological</a>	Yes	CHFT Complies with this	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		<a href="#">myopia) - ranibizumab</a>		NICE TA	
297		<a href="#">Vitreomacular traction - ocriplasmin</a>	Yes	CHFT Complies with this NICE TA	
296		<a href="#">Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib</a>	Yes	CHFT Complies with this NICE TA	
295		<a href="#">Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor): guidance</a>	Yes	CHFT Complies with this NICE TA	
294		<a href="#">Aflibercept solution for injection for treating wet age-related macular degeneration</a>	Yes	CHFT Complies with this NICE TA	
293		<a href="#">Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)</a>	Yes	CHFT Complies with this NICE TA	
292		<a href="#">Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
291		<a href="#">Pegloticase for treating severe debilitating chronic tophaceous gout</a>	Yes	CHFT Complies with this NICE TA	
290		<a href="#">Mirabegron for treating symptoms of overactive bladder</a>	Yes	CHFT Complies with this NICE TA	
289		<a href="#">Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis</a>	Yes	CHFT Complies with this NICE TA	
288		<a href="#">Dapagliflozin in combination therapy for treating type 2 diabetes</a>	Yes	CHFT Complies with this NICE TA	
287		<a href="#">Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism</a>	Yes	CHFT Complies with this NICE TA	
286		<a href="#">Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
285		<a href="#">Bevacizumab in combination with</a>	Yes	CHFT Complies with this	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		<a href="#">gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer</a>		NICE TA	
284		<a href="#">Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer</a>	Yes	CHFT Complies with this NICE TA	
283		<a href="#">Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion</a>	Yes	CHFT Complies with this NICE TA	
282		<a href="#">Pirfenidone for treating idiopathic pulmonary fibrosis</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
281		<a href="#">Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)</a>	Yes	CHFT Complies with this NICE TA	
280		<a href="#">Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234)</a>	Yes	CHFT Complies with this NICE TA	
279		<a href="#">Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures</a>	Yes	CHFT Complies with this NICE TA	
278		<a href="#">Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201)</a>	Yes	CHFT complies with this NICE TA	
277		<a href="#">Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)</a>	Yes	CHFT Complies with this NICE TA	
276		<a href="#">Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis</a>	Yes	CHFT Complies with this NICE TA	
275		<a href="#">Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
274		<a href="#">Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237)</a>	Yes	CHFT Complies with this NICE TA	
273		<a href="#">Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)</a>	Yes	CHFT Complies with this NICE TA	
272		<a href="#">Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
271		<a href="#">Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy</a>	Yes	CHFT Complies with this NICE TA	
270		<a href="#">Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)</a>	Yes	CHFT Complies with this NICE TA	
269		<a href="#">Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
268		<a href="#">Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
267		<a href="#">Ivabradine for treating chronic heart failure</a>	Yes	CHFT Complies with this NICE TA	
266		<a href="#">Mannitol dry powder for inhalation for treating cystic fibrosis</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
265		<a href="#">Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
264		<a href="#">Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122)</a>	Yes	CHFT Complies with this NICE TA	
263		<a href="#">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer</a>	Yes	CHFT Complies with this NICE TA	
262		<a href="#">Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal)</a>	Yes	CHFT Complies with this NICE TA	
261		<a href="#">Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban</a>	Yes	CHFT Complies with this NICE TA	
260		<a href="#">Migraine (chronic) - botulinum toxin type A</a>	Yes	CHFT Complies with this NICE TA	
259		<a href="#">Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy)</a>	Yes	CHFT Complies with this NICE TA	
258		<a href="#">Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)</a>	Yes	CHFT Complies with this NICE TA	
257		<a href="#">Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)</a>	Yes	CHFT Complies with this NICE TA	
256		<a href="#">Atrial fibrillation (stroke prevention) - rivaroxaban</a>	Yes	CHFT Complies with this NICE TA	
255		<a href="#">Prostate cancer - cabazitaxel</a>	Yes	CHFT Complies with this NICE TA	
254		<a href="#">Multiple sclerosis (relapsing-remitting) - fingolimod</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
253		<a href="#">Hepatitis C (genotype 1) - boceprevir</a>	Yes	CHFT Complies with this NICE TA	
252		<a href="#">Hepatitis C (genotype 1) - telaprevir</a>	Yes	CHFT Complies with this NICE TA	
251		<a href="#">Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib</a>	Yes	CHFT Complies with this NICE TA	



Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
250		<a href="#">Breast cancer (advanced) - eribulin</a>	Yes	CHFT Complies with this NICE TA	
249		<a href="#">Atrial fibrillation - dabigatran etexilate</a>	Yes	CHFT Complies with this NICE TA	
248		<a href="#">Diabetes (type 2) - exenatide (prolonged release)</a>	Yes	CHFT Complies with this NICE TA	
247		<a href="#">Rheumatoid arthritis - tocilizumab (rapid review TA198)</a>	Yes	CHFT Complies with this NICE TA	
246		<a href="#">Venom anaphylaxis - immunotherapy pharmlagen</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
245		<a href="#">Venous thromboembolism - apixaban (hip and knee surgery)</a>	Yes	CHFT Complies with this NICE TA	
244		<a href="#">Chronic obstructive pulmonary disease - roflumilast</a>	Yes	CHFT Complies with this NICE TA	
243		<a href="#">Follicular lymphoma - rituximab (review)</a>	Yes	CHFT Complies with this NICE TA	
242		<a href="#">Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)</a>	Yes	CHFT Complies with this NICE TA	
241		<a href="#">Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)</a>	Yes	CHFT Complies with this NICE TA	
240		<a href="#">Colorectal cancer (metastatic) - panitumumab (terminated appraisal)</a>	Yes	CHFT Complies with this NICE TA	
239		<a href="#">Breast cancer (metastatic) - fulvestrant</a>	Yes	CHFT Complies with this NICE TA	
238		<a href="#">Arthritis (juvenile idiopathic, systemic) - tocilizumab</a>	Yes	CHFT Complies with this NICE TA	
237		<a href="#">Macular oedema (diabetic) - ranibizumab</a>	Yes	CHFT Complies with this NICE TA	
236		<a href="#">Acute coronary syndromes - ticagrelor</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
235		<a href="#">Osteosarcoma - mifamurtide</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
234		<a href="#">Rheumatoid arthritis - abatacept (2nd line)</a>	Yes	CHFT Complies with this NICE TA	
233		<a href="#">Ankylosing spondylitis - golimumab</a>	Yes	CHFT Complies with this NICE TA	
232		<a href="#">Epilepsy (partial) - retigabine (adjuvant)</a>	Yes	CHFT Complies with this NICE TA	
231		<a href="#">Depression - agomelatine (terminated appraisal)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
230		<a href="#">Myocardial infarction (persistent ST-segment elevation) - bivalirudin</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
229		<a href="#">Macular oedema (retinal vein occlusion) - dexamethasone</a>	Yes	CHFT Complies with this NICE TA	
228		<a href="#">Multiple myeloma (first line) - bortezomib and thalidomide (TA228)</a>	Yes	CHFT Complies with this NICE TA	
227		<a href="#">Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) (TA227)</a>	Yes	CHFT Complies with this NICE TA	
226		<a href="#">Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)</a>	Yes	CHFT Complies with this NICE TA	
225		<a href="#">Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225)</a>	Yes	CHFT Complies with this NICE TA	
224		<a href="#">Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal) (TA224)</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
223		<a href="#">Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate (TA223)</a>	Yes	CHFT Complies with this NICE TA	
222		<a href="#">Ovarian cancer (relapsed) - trabectedin (TA222)</a>	Yes	CHFT Complies with this NICE TA	
221		<a href="#">Thrombocytopenic purpura - romiplostim (TA221)</a>	Yes	CHFT Complies with this NICE TA	
220		<a href="#">Psoriatic arthritis - golimumab (TA220)</a>	Yes	CHFT Complies with this NICE TA	
219		<a href="#">Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
218		<a href="#">Myelodysplastic syndromes - azacitidine (TA218)</a>	Yes	CHFT Complies with this NICE TA	
217		<a href="#">Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217)</a>	Yes	CHFT Complies with this NICE TA	
216		<a href="#">Leukaemia (lymphocytic) - bendamustine (TA216)</a>	Yes	CHFT Complies with this NICE TA	
215		<a href="#">Renal cell carcinoma (first line metastatic) - pazopanib (TA215)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
214		<a href="#">Breast cancer - bevacizumab (in combination with a taxane) (TA214)</a>	Yes	CHFT Complies with this NICE TA	
213		<a href="#">Schizophrenia - aripiprazole (TA213)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
212		<a href="#">Colorectal cancer (metastatic) - bevacizumab (TA212)</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
211		<a href="#">Constipation (women) - prucalopride (TA211)</a>	Yes	CHFT Complies with this NICE TA	
210		<a href="#">Vascular disease - clopidogrel and dipyridamole (TA210)</a>	Yes	CHFT Complies with this NICE TA	
209		<a href="#">Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
208		<a href="#">Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)</a>	Yes	CHFT Complies with this NICE TA	
207		<a href="#">Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) (TA207)</a>	Yes	CHFT Complies with this NICE TA	
206		<a href="#">Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal) (TA206)</a>	Yes	CHFT Complies with this NICE TA	
205		<a href="#">Thrombocytopenic purpura - eltrombopag (TA205)</a>	Yes	CHFT Complies with this NICE TA	
204		<a href="#">Osteoporotic fractures - denosumab (TA204)</a>	Yes	CHFT Complies with this NICE TA	
203		<a href="#">Diabetes (type 2) - liraglutide (TA203)</a>	Yes	CHFT Complies with this NICE TA	
202		<a href="#">Chronic lymphocytic leukaemia - ofatumumab (TA202)</a>	Yes	CHFT Complies with this NICE TA	
201		<a href="#">Asthma (in children) - omalizumab (TA201)</a>	Yes	CHFT Complies with this NICE TA	
200		<a href="#">Hepatitis C - peginterferon alfa and ribavirin (TA200)</a>	Yes	CHFT Complies with this NICE TA	
199		<a href="#">Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)</a>	Yes	CHFT Complies with this NICE TA	
197		<a href="#">Atrial fibrillation - dronedarone (TA197)</a>	Yes	CHFT Complies with this NICE TA	
196		<a href="#">Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
				requiring management are referred to other organisations	
195		<a href="#">Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)</a>	Yes	CHFT Complies with this NICE TA	
194		<a href="#">Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) (TA194)</a>	Yes	CHFT Complies with this NICE TA	
193		<a href="#">Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)</a>	Yes	CHFT Complies with this NICE TA	
192		<a href="#">Lung cancer (non-small-cell, first line) - gefitinib (TA192)</a>	Yes	CHFT Complies with this NICE TA	
191		<a href="#">Gastric cancer (advanced) - capecitabine (TA191)</a>	Yes	CHFT Complies with this NICE TA	
190		<a href="#">Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)</a>	Yes	CHFT Complies with this NICE TA	
189		<a href="#">Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) (TA189)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
188		<a href="#">Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)</a>	Yes	CHFT Complies with this NICE TA	
187		<a href="#">Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187)</a>	Yes	CHFT Complies with this NICE TA	
186		<a href="#">Rheumatoid arthritis - certolizumab pegol (TA186)</a>	Yes	CHFT Complies with this NICE TA	
185		<a href="#">Soft tissue sarcoma - trabectedin (TA185)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
184		<a href="#">Lung cancer (small-cell) - topotecan (TA184)</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
183		<a href="#">Cervical cancer (recurrent) - topotecan (TA183)</a>	Yes	CHFT Complies with this NICE TA	
182		<a href="#">Acute coronary syndrome - prasugrel (TA182)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
181		<a href="#">Lung cancer (non-small-cell, first line treatment) - pemetrexed (TA181)</a>	Yes	CHFT Complies with this NICE TA	
180		<a href="#">Psoriasis - ustekinumab (TA180)</a>	Yes	CHFT Complies with this NICE TA	
179		<a href="#">Gastrointestinal stromal tumours - sunitinib (TA179)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
178		<a href="#">Renal cell carcinoma (TA178)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
177		<a href="#">Eczema (chronic) - alitretinoin (TA177)</a>	Yes	CHFT Complies with this NICE TA	
176		<a href="#">Colorectal cancer (first line) - cetuximab (TA176)</a>	Yes	CHFT Complies with this NICE TA	
175		<a href="#">Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) (TA175)</a>	Yes	CHFT Complies with this NICE TA	
174		<a href="#">Leukaemia (chronic lymphocytic, first line) - rituximab (TA174)</a>	Yes	CHFT Complies with this NICE TA	
173		<a href="#">Hepatitis B - tenofovir disoproxil fumarate (TA173)</a>	Yes	CHFT Complies with this NICE TA	
172		<a href="#">Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
				referred to other organisations	
171		<a href="#">Multiple myeloma - lenalidomide (TA171)</a>	Yes	CHFT Complies with this NICE TA	
170		<a href="#">Venous thromboembolism - rivaroxaban (TA170)</a>	Yes	CHFT Complies with this NICE TA	
169		<a href="#">Renal cell carcinoma - sunitinib (TA169)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
168		<a href="#">Influenza - zanamivir, amantadine and oseltamivir (review) (TA168)</a>	Yes	CHFT Complies with this NICE TA	
167		<a href="#">Abdominal aortic aneurysm - endovascular stent-grafts (TA167)</a>	Yes	CHFT Complies with this NICE TA	
166		<a href="#">Hearing impairment - cochlear implants (TA166)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
165		<a href="#">Organ preservation (renal) - machine perfusion and static storage (TA165)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
164		<a href="#">Hyperuricaemia - febuxostat (TA164)</a>	Yes	CHFT Complies with this NICE TA	
163		<a href="#">Ulcerative colitis (acute exacerbations) - infliximab (TA163)</a>	Yes	CHFT Complies with this NICE TA	
162		<a href="#">Lung cancer (non-small-cell) - erlotinib (TA162)</a>	Yes	CHFT Complies with this NICE TA	
161		<a href="#">Osteoporosis - secondary prevention including strontium ranelate (TA161)</a>	Yes	CHFT Complies with this NICE TA	
160		<a href="#">Osteoporosis - primary prevention (TA160)</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
159		<a href="#">Pain (chronic neuropathic or ischaemic) - spinal cord stimulation (TA159)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
158		<a href="#">Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158)</a>	Yes	CHFT Complies with this NICE TA	
157		<a href="#">Venous thromboembolism - dabigatran (TA157)</a>	Yes	CHFT Complies with this NICE TA	
156		<a href="#">Pregnancy (rhesus negative women) - routine anti-D (review) (TA156)</a>	Yes	CHFT Complies with this NICE TA	
155		<a href="#">Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155)</a>	Yes	CHFT Complies with this NICE TA	
154		<a href="#">Hepatitis B - telbivudine (TA154)</a>	Yes	CHFT Complies with this NICE TA	
153		<a href="#">Hepatitis B - entecavir (TA153)</a>	Yes	CHFT Complies with this NICE TA	
152		<a href="#">Coronary artery disease - drug-eluting stents (TA152)</a>	Yes	CHFT Complies with this NICE TA	
151		<a href="#">Diabetes - insulin pump therapy (TA151)</a>	Yes	CHFT Complies with this NICE TA	
149		<a href="#">Glioma (recurrent) - carmustine implants (terminated appraisal) (TA149)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
148		<a href="#">Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) (TA148)</a>	Yes	CHFT Complies with this NICE TA	
146		<a href="#">Psoriasis - adalimumab (TA146)</a>	Yes	CHFT Complies with this NICE TA	
145		<a href="#">Head and neck cancer - cetuximab (TA145)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	



Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
143		<a href="#">Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)</a>	Yes	CHFT Complies with this NICE TA	
142		<a href="#">Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin (TA142)</a>	Yes	CHFT Complies with this NICE TA	
140		<a href="#">Ulcerative colitis (subacute manifestations) - infliximab (TA140)</a>	Yes	CHFT Complies with this NICE TA	
139		<a href="#">Sleep apnoea - continuous positive airway pressure (CPAP) (TA139)</a>	Yes	CHFT Complies with this NICE TA	
138		<a href="#">Asthma (in adults) - corticosteroids (TA138)</a>	Yes	CHFT Complies with this NICE TA	
137		<a href="#">Lymphoma (follicular non-Hodgkin's) - rituximab (TA137)</a>	Yes	CHFT Complies with this NICE TA	
136		<a href="#">Structural neuroimaging in first-episode psychosis (TA136)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
135		<a href="#">Mesothelioma - pemetrexed disodium (TA135)</a>	Yes	CHFT Complies with this NICE TA	
134		<a href="#">Psoriasis - infliximab (TA134)</a>	Yes	CHFT Complies with this NICE TA	
133		<a href="#">Asthma (uncontrolled) - omalizumab (TA133)</a>	Yes	CHFT Complies with this NICE TA	
132		<a href="#">Hypercholesterolaemia - ezetimibe (TA132)</a>	Yes	CHFT Complies with this NICE TA	
131		<a href="#">Asthma (in children) - corticosteroids (TA131)</a>	Yes	CHFT Complies with this NICE TA	
130		<a href="#">Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130)</a>	Yes	CHFT Complies with this NICE TA	
129		<a href="#">Multiple myeloma - bortezomib (TA129)</a>	Yes	CHFT Complies with this NICE TA	
128		<a href="#">Haemorrhoid - stapled haemorrhoidopexy (TA128)</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
127		<a href="#">Multiple sclerosis - natalizumab (TA127)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
124		<a href="#">Lung cancer (non-small-cell) - pemetrexed (TA124)</a>	Yes	CHFT Complies with this NICE TA	
123		<a href="#">Smoking cessation - varenicline (TA123)</a>	Yes	CHFT Complies with this NICE TA	
122		<a href="#">Ischaemic stroke (acute) - alteplase (TA122)</a>	Yes	CHFT Complies with this NICE TA	
121		<a href="#">Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
120		<a href="#">Heart failure - cardiac resynchronisation (TA120)</a>	Yes	CHFT Complies with this NICE TA	
119		<a href="#">Leukaemia (lymphocytic) - fludarabine (TA119)</a>	Yes	CHFT Complies with this NICE TA	
118		<a href="#">Colorectal cancer (metastatic) - bevacizumab and cetuximab (TA118) (partially updated by TA242)</a>	Yes	CHFT Complies with this NICE TA	
117		<a href="#">Hyperparathyroidism - cinacalcet (TA117)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
116		<a href="#">Breast cancer - gemcitabine (TA116)</a>	Yes	CHFT Complies with this NICE TA	
115		<a href="#">Drug misuse - naltrexone (TA115)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
114		<a href="#">Drug misuse - methadone and buprenorphine (TA114)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
112		<a href="#">Breast cancer (early) - hormonal treatments (TA112)</a>	Yes	CHFT Complies with this NICE TA	
109		<a href="#">Breast cancer (early) - docetaxel (TA109)</a>	Yes	CHFT Complies with this NICE TA	
108		<a href="#">Breast cancer (early) - paclitaxel (TA108)</a>	Yes	CHFT Complies with this NICE TA	
107		<a href="#">Breast cancer (early) - trastuzumab (TA107)</a>	Yes	CHFT Complies with this NICE TA	
106		<a href="#">Hepatitis C - peginterferon alfa and ribavirin (TA106)</a>	Yes	CHFT Complies with this NICE TA	
105		<a href="#">Colorectal cancer - laparoscopic surgery (review) (TA105)</a>	Yes	CHFT Complies with this NICE TA	
103		<a href="#">Psoriasis - efalizumab and etanercept (TA103)</a>	Yes	CHFT Complies with this NICE TA	
102		<a href="#">Conduct disorder in children - parent-training/education programmes (TA102)</a>	Yes	CHFT Complies with this NICE TA	
101		<a href="#">Prostate cancer (hormone-refractory) - docetaxel (TA101)</a>	Yes	CHFT Complies with this NICE TA	
100		<a href="#">Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)</a>	Yes	CHFT Complies with this NICE TA	
99		<a href="#">Renal transplantation - immunosuppressive regimens for children and adolescents (TA99)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
98		<a href="#">Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (TA98)</a>	Yes	CHFT Complies with this NICE TA	
97		<a href="#">Depression and anxiety - computerised</a>	TA Not Applicable to services provided by	CHFT does not treat patients	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
		<a href="#">cognitive behavioural therapy (CCBT) (TA97)</a>	this organisation	with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
96		<a href="#">Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (TA96)</a>	Yes	CHFT Complies with this NICE TA	
95		<a href="#">Arrhythmia - implantable cardioverter defibrillators (ICDs) (review) (TA95)</a>	Yes	CHFT Complies with this NICE TA	
94		<a href="#">Cardiovascular disease - statins (TA94)</a>	Yes	CHFT Complies with this NICE TA	
92		<a href="#">Tooth decay - HealOzone (TA92)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
91		<a href="#">Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (TA91)</a>	Yes	CHFT Complies with this NICE TA	
88		<a href="#">Bradycardia - dual chamber pacemakers (TA88)</a>	Yes	CHFT Complies with this NICE TA	
86		<a href="#">Gastrointestinal stromal tumours - imatinib (TA86)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
85		<a href="#">Renal transplantation - immuno-suppressive regimens (adults) (TA85)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
83		<a href="#">Hernia - laparoscopic surgery (review) (TA83)</a>	Yes	CHFT Complies with this NICE TA	
82		<a href="#">Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
81		<a href="#">Atopic dermatitis (eczema) - topical steroids (TA81)</a>	Yes	CHFT Complies with this NICE TA	
78		<a href="#">Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation (TA78)</a>	Yes	CHFT Complies with this NICE TA	
77		<a href="#">Insomnia - newer hypnotic drugs (TA77)</a>	Yes	CHFT Complies with this NICE TA	
75		<a href="#">Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75)</a>	Yes	CHFT Complies with this NICE TA	
74		<a href="#">Trauma - fluid replacement therapy (TA74)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
73		<a href="#">Angina and myocardial infarction - myocardial perfusion scintigraphy (TA73)</a>	Yes	CHFT Complies with this NICE TA	
71		<a href="#">Ischaemic heart disease - coronary artery stents (TA71)</a>	Yes	CHFT Complies with this NICE TA	
70		<a href="#">Leukaemia (chronic myeloid) - imatinib (TA70) (partially updated by TA241 and TA251)</a>	Yes	CHFT Complies with this NICE TA	
69		<a href="#">Cervical cancer - cervical screening (review) (TA69)</a>	Yes	CHFT Complies with this NICE TA	
68		<a href="#">Macular degeneration (age-related) - photodynamic therapy (TA68)</a>	Yes	CHFT Complies with this NICE TA	
65		<a href="#">Non-Hodgkin's lymphoma - rituximab (TA65)</a>	Yes	CHFT Complies with this NICE TA	
64		<a href="#">Growth hormone deficiency (adults) - human growth hormone (TA64)</a>	Yes	CHFT Complies with this NICE TA	
61		<a href="#">Colorectal cancer - capecitabine and tegafur uracil (TA61)</a>	Yes	CHFT Complies with this NICE TA	
60		<a href="#">Diabetes (types 1 and 2) - patient education models (TA60)</a>	Yes	CHFT Complies with this NICE TA	
59		<a href="#">Electroconvulsive therapy (ECT) (TA59)</a>	TA Not Applicable to services provided by	CHFT does not treat patients	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
			this organisation	with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
55		<a href="#">Ovarian cancer - paclitaxel (review) (TA55)</a>	Yes	CHFT Complies with this NICE TA	
53		<a href="#">Diabetes (types 1 and 2) - long acting insulin analogues (TA53)</a>	Yes	CHFT Complies with this NICE TA	
52		<a href="#">Myocardial infarction - thrombolysis (TA52)</a>	Yes	CHFT Complies with this NICE TA	
49		<a href="#">Central venous catheters - ultrasound locating devices (TA49)</a>	Yes	CHFT Complies with this NICE TA	
48		<a href="#">Renal failure - home versus hospital haemodialysis (TA48)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
47		<a href="#">Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47) (partially updated by CG94)</a>	Yes	CHFT Complies with this NICE TA	
44		<a href="#">Hip disease - metal on metal hip resurfacing (TA44)</a>	Yes	CHFT Complies with this NICE TA	
38		<a href="#">Asthma (older children) - inhaler devices (TA38)</a>	Yes	CHFT Complies with this NICE TA	
35		<a href="#">Arthritis (juvenile idiopathic) - etanercept (TA35)</a>	Yes	CHFT Complies with this NICE TA	
34		<a href="#">Breast cancer - trastuzumab (TA34)</a>	Yes	CHFT Complies with this NICE TA	
32		<a href="#">Multiple sclerosis - beta interferon and glatiramer acetate (TA32)</a>	TA Not Applicable to services provided by this organisation	CHFT Complies with this NICE TA	
29		<a href="#">Leukaemia (lymphocytic) - fludarabine (TA29)</a>	Yes	CHFT Complies with this NICE TA	
25		<a href="#">Pancreatic cancer - gemcitabine (TA25)</a>	Yes	CHFT Complies with this NICE TA	

Technology Appraisal Number	Published	Title	Has the recommendation in the TA been implemented in the organisation for example by changes to the local formulary for drugs or procurement of devices? (Yes/No/TA Not Applicable to this organisation)	Does CHFT Comply with the NICE Technology Appraisal (Yes/No/TA Not Applicable to this organisation)	Date Approved at MMC
23		<a href="#">Brain cancer - temozolomide (TA23)</a>	TA Not Applicable to services provided by this organisation	CHFT does not treat patients with the condition covered by this NICE TA - patients requiring management are referred to other organisations	
20		<a href="#">Motor neurone disease - riluzole (TA20)</a>	Yes	CHFT Complies with this NICE TA	
10		<a href="#">Asthma (children under 5) - inhaler devices (TA10)</a>	Yes	CHFT Complies with this NICE TA	
2		<a href="#">Hip disease - replacement prostheses (TA2)</a>	Yes	CHFT Complies with this NICE TA	
1		<a href="#">Wisdom teeth - removal (TA1)</a>	Yes	CHFT Complies with this NICE TA	